Abstract 7P
Background
RNA modifications play an important role in gene expression and cellular functions. Regulatory genes for RNA modifications, such as methyltransferase 1, tRNA methylguanosine (METTL1) and adenosine deaminase RNA specific B1 (ADAR2), have been correlated with cancer progression due to their effects on mRNA and tRNA editing.
Methods
In this study, the association between polymorphisms in 25 RNA modification regulatory genes and the prognosis of 744 non-small cell lung cancer (NSCLC) patients was evaluated. Among the 21 single nucleotide polymorphisms (SNPs) studied, three were significantly associated with the overall survival (OS) of patients.
Results
The SNP rs10877013T>C in METTL1 gene was significantly associated with better OS (under a dominant model, adjusted hazard ratio [aHR] = 0.67, 95% confidence interval [CI] = 0.48-0.93, P = 0.02). METTL1 rs10877013 is located in intronic region, so rs703842G>A located in METTL13′untranslated region (3′UTR) with a strong LD (D′ = 1.0 and r2 ≥ 0.9) was found. The SNPs rs3788152A>C and rs414743G>A in the ADAR2 gene were associated with significantly worse OS (under a dominant model, aHR = 1.46, 95% CI = 1.05-2.03, P = 0.03; under a codominant model, aHR = 1.40, 95% CI = 1.02-1.93, P = 0.04, respectively). A dual luciferase assay showed a significantly higher promoter activity of METTL1 with the rs703842 A allele than with the G allele in H1299 (P = 6.5×10-6) and H1703 lung cancer cells (P = 0.03). Knockdown of METTL1 with specific siRNA induced cell apoptosis and decreased cell proliferation, invasion, and migration in lung cancer cells.
Conclusions
In conclusion, the investigation reveals that genetic variations METTL1 rs10877013T>C, ADAR2 rs3788152A>C, and ADAR2 rs414743G>A polymorphisms within RNA modification regulatory genes are associated with survival outcomes of NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1781P - Multi-omics of soft tissue sarcomas with complex karyotypes: Investigating genomic and transcriptomic differences between cell lines of the same subtype
Presenter: Miriam Arrulo
Session: Poster session 07
1782P - Assessing the role of denosumab in managing aneurysmal bone cysts: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 07
1783P - Genetic predisposition in adult sarcoma patients: Beyond TP53
Presenter: Olivia Rohr
Session: Poster session 07
1784TiP - Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study
Presenter: Richard Schlenk
Session: Poster session 07
1785TiP - PERELI, a phase II, open label, multicenter study of pemigatinib and retifanlimab in advanced dedifferentiated liposarcoma
Presenter: Helena Nyström
Session: Poster session 07
1787P - Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study
Presenter: Melissa Johnson
Session: Poster session 07
1790P - Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d)
Presenter: Jon Zugazagoitia
Session: Poster session 07